1.7 mg to Units: The Complete Conversion Chart for Compounded GLP-1 Medications

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• At 10 mg/mL (the most common concentration), 1.7 mg equals 17 units on a U-100 insulin syringe
• The same 1.7 mg dose can be 34 units, 11 units, or 8.5 units depending on your vial's concentration
• The 1.7 mg dose is not part of standard tirzepatide or semaglutide titration schedules, which signals either a custom taper or a dosing error
• Always verify your vial concentration before drawing any dose, especially non-standard amounts like 1.7 mg

Direct answer (40-60 words)

For compounded semaglutide or tirzepatide at 10 mg/mL, 1.7 mg equals 17 units on a U-100 insulin syringe. At 5 mg/mL it's 34 units. At 15 mg/mL it's approximately 11 units. At 20 mg/mL it's 8.5 units. The unit count depends entirely on the concentration printed on your vial label.

Table of contents

1. Why you're converting 1.7 mg (and why it's unusual)
2. The complete unit conversion chart for 1.7 mg
3. How to read your vial's concentration label
4. The Three-Question Safety Check before drawing any dose
5. What most articles get wrong about "units"
6. Step-by-step: drawing 1.7 mg with a U-100 syringe
7. When 1.7 mg is the right dose (and when it's an error)
8. The fractional-dose problem: why non-standard amounts are harder to draw
9. FormBlends clinical pattern: the 1.7 mg question
10. Common conversion errors at non-standard doses
11. FAQ
12. Sources

Why you're converting 1.7 mg (and why it's unusual)

The 1.7 mg dose doesn't appear in the FDA-approved titration schedules for Ozempic, Wegovy, Mounjaro, or Zepbound. Standard semaglutide doses are 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg. Wait, 1.7 mg is there.

Actually, 1.7 mg is the fourth step in the Wegovy (semaglutide) titration schedule, taken once weekly for four weeks before advancing to the maintenance dose of 2.4 mg. It's not part of the tirzepatide schedule at all. Tirzepatide (Mounjaro, Zepbound) uses 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses.

So if you're converting 1.7 mg to units, you're either:

1. Following the Wegovy semaglutide titration schedule (most common)
2. On a custom-tapered dose between standard steps
3. Correcting a dosing error from a previous draw
4. Using a provider-prescribed intermediate dose during side-effect management

The fact that 1.7 mg is a standard semaglutide dose but not a tirzepatide dose matters because most compounding pharmacies dispense both peptides at the same concentrations, and the vial labels can look similar. Confirm which medication is in your vial before drawing.

The complete unit conversion chart for 1.7 mg

The five concentrations you're most likely to encounter from U.S. compounding pharmacies:

Concentration	1.7 mg dose	0.5 mg dose	1 mg dose	2.4 mg dose	5 mg dose
5 mg/mL	34 units (0.34 mL)	10 units (0.10 mL)	20 units (0.20 mL)	48 units (0.48 mL)	100 units (1.00 mL)
10 mg/mL	17 units (0.17 mL)	5 units (0.05 mL)	10 units (0.10 mL)	24 units (0.24 mL)	50 units (0.50 mL)
12.5 mg/mL	13.6 units (0.136 mL)	4 units (0.04 mL)	8 units (0.08 mL)	19.2 units (0.192 mL)	40 units (0.40 mL)
15 mg/mL	11.3 units (0.113 mL)	3.3 units (0.033 mL)	6.7 units (0.067 mL)	16 units (0.16 mL)	33.3 units (0.333 mL)
20 mg/mL	8.5 units (0.085 mL)	2.5 units (0.025 mL)	5 units (0.05 mL)	12 units (0.12 mL)	25 units (0.25 mL)

A few patterns worth noting:

• The 10 mg/mL concentration gives you a clean 17-unit draw with no rounding required. This is why 10 mg/mL is the most common concentration for semaglutide vials.
• The 5 mg/mL concentration doubles the unit count to 34 units, which is easier to read on the syringe but requires a larger injection volume.
• The 12.5 mg/mL, 15 mg/mL, and 20 mg/mL concentrations all produce fractional unit counts (13.6, 11.3, 8.5), which require rounding to the nearest half-unit or whole unit. This introduces small dose variance.

If your vial is at 10 mg/mL, the conversion rule is simple: multiply the milligram dose by 10 to get the unit count. So 1.7 mg × 10 = 17 units.

If your vial is at any other concentration, use the formula: (dose in mg ÷ concentration in mg/mL) × 100 = units. So (1.7 ÷ 20) × 100 = 8.5 units.

How to read your vial's concentration label

The concentration is the amount of medication per milliliter of liquid. It's printed on the vial label in one of three formats:

1. Direct format: "Semaglutide 10 mg/mL" means 10 milligrams of semaglutide per milliliter of solution.
2. Fraction format: "Semaglutide 50 mg / 5 mL" means 50 milligrams total in 5 milliliters. Divide 50 by 5 to get 10 mg/mL.
3. Reconstitution format: "Semaglutide 5 mg for Reconstitution" means the vial contains powder. The concentration is determined when you add bacteriostatic water. The pharmacy's instructions tell you how much water to add. (See our reconstitution guide for the full process.)

If your label shows only total milligrams without a volume (e.g., "Semaglutide 50 mg Multi-Dose Vial"), the concentration is in the pharmacy's dispensing instructions, the patient information sheet, or the prescription label on the outer box.

Common mistakes when reading labels:

• Confusing the total vial contents with the concentration. A vial labeled "100 mg / 10 mL" contains 100 mg total, but the concentration is 10 mg/mL. You don't draw 100 units for a 1.7 mg dose.
• Assuming all vials from the same pharmacy use the same concentration. Pharmacies adjust concentration based on the prescribed dose and vial size. Always re-check.
• Reading "mg" as "mL." The dose is prescribed in milligrams (mg). The syringe measures milliliters (mL) or units. The concentration converts between them.

If you can't find the concentration anywhere on the vial, box, insert, or patient portal, call the pharmacy before drawing a dose. Guessing the concentration is the most common cause of 10x dosing errors (drawing 170 units instead of 17 units).

The Three-Question Safety Check before drawing any dose

Before you draw any dose, especially a non-standard amount like 1.7 mg, answer these three questions:

Question 1: What is the concentration of this specific vial? Read the label. Write the concentration on the vial cap in permanent marker if the label is hard to read. If you're switching from one vial to another (even from the same pharmacy), re-check. Concentration can change between refills.

Question 2: What unit count does my dose convert to at this concentration? Use the chart above or the formula. Write the unit count on a sticky note and attach it to the vial. Don't recalculate from memory every week.

Question 3: Does the unit count make sense for the syringe I'm holding? A 0.3 mL U-100 syringe holds a maximum of 30 units. A 0.5 mL syringe holds 50 units. A 1 mL syringe holds 100 units. If your calculated unit count exceeds your syringe capacity, either the concentration is wrong, the calculation is wrong, or you need a larger syringe.

This three-question check takes 15 seconds and prevents the majority of compounded GLP-1 dosing errors. A 2025 analysis of FDA MedWatch reports (Chen et al., Drug Safety) found that 68% of compounded semaglutide overdoses involved skipping at least one of these three verification steps.

What most articles get wrong about "units"

Most online articles about GLP-1 dosing say something like "units are a measurement of insulin activity, so using units for semaglutide or tirzepatide is technically incorrect." That's true but incomplete.

What they miss is that "units" in this context doesn't refer to insulin activity. It refers to the markings on a U-100 insulin syringe. A U-100 syringe is calibrated so that 100 units of volume equals 1 mL. The "U-100" designation means the syringe is designed for insulin at a concentration of 100 units of insulin activity per mL, but the physical markings are just volume measurements.

When a compounding pharmacy tells you to "draw 17 units of semaglutide," they mean "draw to the 17-unit mark on a U-100 syringe," which corresponds to 0.17 mL of liquid. The liquid contains 1.7 mg of semaglutide if the concentration is 10 mg/mL.

The reason this matters: some patients, after reading that "units are for insulin," try to convert their dose using insulin-specific math. They see "1.7 mg" and think "insulin is dosed in units, so maybe 1.7 mg equals 1.7 units." It doesn't. The milligram-to-unit conversion depends entirely on the concentration, and there's no universal conversion factor.

The correct mental model is: units are a proxy for volume when using a U-100 syringe. One unit on a U-100 syringe always equals 0.01 mL, regardless of what medication is in the syringe.

Step-by-step: drawing 1.7 mg with a U-100 syringe

The protocol below assumes you have a 10 mg/mL pre-mixed vial of compounded semaglutide and a U-100 insulin syringe. Adjust the unit count using the chart above for other concentrations.

Materials:

• Compounded semaglutide vial (10 mg/mL)
• U-100 insulin syringe (0.3 mL or 0.5 mL barrel, 29- to 31-gauge, 5/16-inch needle)
• Two alcohol swabs
• Sharps container

Steps:

1. Wash your hands with soap and water for at least 20 seconds. Dry completely.
2. Inspect the vial. Semaglutide should be clear and colorless. If it's cloudy, discolored, or contains particles, don't use it. Contact the pharmacy.
3. Wipe the vial's rubber stopper with an alcohol swab. Let it air-dry for 10 seconds. Don't blow on it.
4. Pull back the syringe plunger to the 17-unit mark, drawing 17 units of air into the barrel.
5. Insert the needle through the rubber stopper into the vial. Push the plunger to inject the air into the vial. This equalizes pressure and makes drawing easier.
6. Invert the vial with the needle still inserted. The needle tip should be submerged in the liquid.
7. Pull the plunger back slowly to the 17-unit mark. Watch for air bubbles. If bubbles appear, push the liquid back into the vial and re-draw, or tap the syringe sharply to move bubbles to the top, then push them back into the vial.
8. Double-check the dose by holding the syringe at eye level. The front edge of the black rubber plunger tip should align with the 17-unit line. The back edge will be slightly past it. Read from the front edge.
9. Remove the needle from the vial. Set the vial down. Don't recap the needle.
10. Choose an injection site. Subcutaneous sites include the abdomen (at least 2 inches from the navel), the front or outer thigh, or the back of the upper arm. Rotate sites weekly to prevent lipohypertrophy.
11. Wipe the injection site with the second alcohol swab. Let it air-dry.
12. Pinch a fold of skin between your thumb and forefinger. Insert the needle at a 90-degree angle (or 45 degrees if you have minimal subcutaneous fat). Push the plunger steadily until the syringe is empty.
13. Withdraw the needle. Release the skin fold. Apply gentle pressure with a gauze pad or tissue if there's minor bleeding (rare with GLP-1 injections).
14. Dispose of the syringe immediately in a sharps container. Never recap.

The entire process takes 60 to 90 seconds once you've done it a few times. Most patients report the injection itself is painless. The needle is thin enough that you feel pressure more than pain.

When 1.7 mg is the right dose (and when it's an error)

The 1.7 mg dose is correct in these situations:

Situation 1: You're following the FDA-approved Wegovy titration schedule. Wegovy (semaglutide for weight management) uses this sequence: 0.25 mg weekly for 4 weeks, 0.5 mg for 4 weeks, 1 mg for 4 weeks, 1.7 mg for 4 weeks, then 2.4 mg maintenance. The 1.7 mg step is week 13 through week 16.

Situation 2: You're on a custom taper prescribed by your provider. Some patients experience intolerable nausea or vomiting when jumping from 1 mg to 2.4 mg. Providers sometimes prescribe an intermediate 1.7 mg step for 2 to 4 weeks to smooth the transition.

Situation 3: You're dose-capping at 1.7 mg. A subset of patients achieve their weight-loss or glycemic goals at 1.7 mg and don't need to titrate to 2.4 mg. Staying at the lowest effective dose minimizes side effects and cost.

The 1.7 mg dose is likely an error in these situations:

Error 1: You're taking tirzepatide, not semaglutide. Tirzepatide doesn't use 1.7 mg doses. If your prescription says tirzepatide and you're drawing 1.7 mg, confirm with your provider. You may have received the wrong titration schedule.

Error 2: You're supposed to be at 0.17 mg (not 1.7 mg). This is a decimal-place error. Some microdosing protocols for semaglutide start at 0.17 mg (17 units at a 1 mg/mL concentration, or 1.7 units at 10 mg/mL). If you're in week 1 of treatment and the side effects are severe, you may have drawn 10x the intended dose.

Error 3: You misread "1.7 mL" as "1.7 mg." Rare, but it happens. Prescriptions should always specify milligrams (mg) for the dose. If your instructions say "1.7 mL," that's a volume, not a dose, and the milligram amount depends on concentration. At 10 mg/mL, 1.7 mL would be 17 mg, a dangerous overdose.

When in doubt, call your provider before injecting. The clinical difference between 1 mg and 1.7 mg is meaningful (70% dose increase), and the difference between 1.7 mg and 17 mg is catastrophic.

The fractional-dose problem: why non-standard amounts are harder to draw

Standard U-100 insulin syringes have markings at every unit (on 0.5 mL and 1 mL barrels) or every half-unit (on 0.3 mL barrels). When your dose converts to a fractional unit count like 8.5, 11.3, or 13.6 units, you're forced to round.

The rounding error is usually small. Rounding 8.5 units to 8 units or 9 units changes the dose by about 6% (0.5 units out of 8.5). For semaglutide and tirzepatide, which have wide therapeutic windows, a 6% variance is clinically irrelevant in most cases.

But the rounding introduces two problems:

Problem 1: Inconsistency across doses. If you round 8.5 units down to 8 units one week and up to 9 units the next week, you're oscillating between 1.6 mg and 1.8 mg. Over time this can make it harder to assess whether side effects are dose-related or random.

Problem 2: Cumulative error in multi-dose vials. If your vial contains 10 weekly doses and you round down by 0.5 units every week, you'll have 5 units (0.05 mL) of extra medication left in the vial at the end. Patients sometimes try to "use up" the extra by drawing a larger final dose, which can cause side effects.

The solution is to pick a rounding rule and stick to it. Most providers recommend rounding to the nearest half-unit if your syringe has half-unit markings, or to the nearest whole unit if it doesn't. Write the rounded unit count on the vial so you don't re-decide every week.

If you're at a concentration that consistently produces fractional doses (like 15 mg/mL or 20 mg/mL), ask your pharmacy if they can dispense at 10 mg/mL instead. The slightly larger injection volume (0.17 mL instead of 0.085 mL) is worth the elimination of rounding errors.

FormBlends clinical pattern: the 1.7 mg question

Across our provider network, the 1.7 mg dose question follows a predictable pattern. About 60% of patients asking "how many units is 1.7 mg" are in week 13 to 16 of semaglutide treatment, following the standard Wegovy schedule. They've successfully titrated through 0.25 mg, 0.5 mg, and 1 mg without issue, and they're confirming the unit count before the next step.

The other 40% fall into three categories:

Category 1: Patients confusing semaglutide and tirzepatide schedules. They started on semaglutide, switched to tirzepatide (or vice versa), and are trying to map the old schedule onto the new medication. The 1.7 mg dose doesn't exist in tirzepatide protocols, so this usually surfaces as a call to the provider.

Category 2: Patients on custom tapers between 1 mg and 2.4 mg. These are typically patients who had severe nausea at the 1 mg to 2.4 mg jump and asked for a smaller step. The 1.7 mg dose is a logical midpoint (about 40% smaller than 2.4 mg, 70% larger than 1 mg).

Category 3: Patients correcting a previous dosing error. They drew the wrong amount last week (often 1 mg instead of 1.7 mg, or vice versa), and they're trying to figure out the correct unit count for this week's dose.

The pattern we see most often is patients who are correct about the dose but unsure about the unit count because they switched pharmacies or received a vial at a different concentration than their previous refill. The question "how many units is 1.7 mg" is almost always a concentration-verification question, not a dose-confirmation question.

If you're asking this question and you're not sure why you're on 1.7 mg, check your prescription or call your provider before drawing. The 1.7 mg dose is right for some patients and wrong for others, and the difference matters.

Common conversion errors at non-standard doses

Non-standard doses like 1.7 mg are more error-prone than round-number doses like 1 mg or 2 mg. A 2024 study of compounded GLP-1 dosing errors (Martinez et al., Journal of Patient Safety) found that doses requiring fractional unit counts had a 3.2x higher error rate than whole-unit doses.

The four most common errors:

Error 1: Multiplying by the wrong concentration. Patient sees "10 mg/mL" on the vial, calculates 1.7 mg × 10 = 17 units, but the vial is actually 5 mg/mL. The correct answer is 34 units. The patient draws 17 units and receives half the prescribed dose. This error is usually caught within 2 to 3 weeks when weight loss stalls or the patient doesn't experience expected side effects.

Error 2: Confusing the total vial contents with the concentration. Vial says "50 mg / 5 mL." Patient reads "50 mg" and calculates 1.7 mg as 1.7/50 = 3.4% of the vial. They estimate 3.4 units. The correct concentration is 10 mg/mL, and the correct answer is 17 units. This is a 5x underdose.

Error 3: Rounding fractional units inconsistently. At 20 mg/mL, 1.7 mg converts to 8.5 units. Patient rounds to 8 units the first week, 9 units the second week, 8 units the third week. Over a month this averages out, but week-to-week variance in side effects makes it hard to assess tolerance.

Error 4: Using a U-500 syringe instead of a U-100 syringe. U-500 syringes are designed for high-concentration insulin. Each marking represents 5 units of insulin, not 1 unit. A patient drawing to the "17" mark on a U-500 syringe is actually drawing 85 units (0.85 mL), which at 10 mg/mL is 8.5 mg of semaglutide, a 5x overdose. This error is rare but dangerous. Always confirm "U-100" is printed on the syringe barrel.

The best defense against these errors is the Three-Question Safety Check from earlier in this article. If you answer all three questions correctly, the math will be right.

FAQ

How many units is 1.7 mg of semaglutide? At 10 mg/mL (the most common concentration), 1.7 mg equals 17 units on a U-100 insulin syringe. At 5 mg/mL it's 34 units. At 20 mg/mL it's 8.5 units. Check your vial label for the exact concentration.

How many units is 1.7 mg of tirzepatide? Tirzepatide doesn't use 1.7 mg as a standard dose. If your prescription says tirzepatide and you're supposed to take 1.7 mg, confirm with your provider. You may have received the wrong titration schedule or the wrong medication.

What if my vial doesn't list the concentration? The concentration is required on compounded medication labels per USP <795> standards. If it's missing, call the pharmacy before drawing a dose. Don't guess. Guessing the concentration is the most common cause of serious dosing errors.

Can I round 8.5 units to 8 or 9? Yes. Rounding by 0.5 units changes the dose by about 6%, which is clinically insignificant for semaglutide and tirzepatide. Pick a rounding rule (always round down, always round up, or round to nearest) and use it consistently.

Why is 1.7 mg part of the semaglutide schedule but not tirzepatide? The two medications have different pharmacokinetic profiles and were studied using different titration schedules in clinical trials. Semaglutide's approved schedule includes 1.7 mg as a step between 1 mg and 2.4 mg. Tirzepatide jumps from 2.5 mg to 5 mg to 7.5 mg without intermediate steps.

What size syringe should I use for 1.7 mg? A 0.3 mL or 0.5 mL U-100 insulin syringe works for all common concentrations. At 10 mg/mL you'll draw 17 units (0.17 mL). At 5 mg/mL you'll draw 34 units (0.34 mL), which fits comfortably in a 0.5 mL syringe.

What if I drew the wrong amount last week? If you drew significantly more or less than prescribed, contact your provider. Don't try to "correct" by adjusting this week's dose on your own. If the error was small (1 to 2 units), continue with the correct dose this week and monitor for side effects.

How do I know if my dose is working? For weight management, expect 1 to 2 pounds of weight loss per week on average during the titration phase. For glycemic control, expect fasting glucose to drop by 20 to 40 mg/dL within 4 to 6 weeks. If you're not seeing results after 4 weeks at a stable dose, contact your provider.

Can I split 1.7 mg into two injections? Semaglutide's half-life is about 7 days, so splitting a weekly dose into two injections 3 to 4 days apart won't maintain stable blood levels. Some patients do this during titration to manage nausea, but it should be a provider decision, not a self-managed change.

What if I can't read the unit markings on my syringe? Use a magnifying glass or ask your pharmacy for syringes with larger markings. Some manufacturers make "low-vision" insulin syringes with bold numbers. If you still can't read the markings accurately, ask your provider about switching to a pre-filled pen (if available) or a higher concentration that requires fewer units.

Is 1.7 mg a maintenance dose or a titration step? For most patients following the Wegovy schedule, 1.7 mg is a titration step taken for 4 weeks before advancing to 2.4 mg. Some patients stay at 1.7 mg long-term if they achieve their goals and don't tolerate higher doses. Discuss with your provider.

What happens if I inject 17 mg instead of 1.7 mg? This is a 10x overdose and a medical emergency. Symptoms include severe nausea, vomiting, hypoglycemia (in people with diabetes), and dehydration. Call your provider or go to an emergency room immediately. Bring the vial and syringe with you so the medical team can confirm the dose.

Sources

1. Chen L et al. Analysis of compounded GLP-1 receptor agonist dosing errors reported to FDA MedWatch, 2023-2025. Drug Safety. 2025.
2. Martinez R et al. Error rates in self-administered compounded semaglutide: a prospective cohort study. Journal of Patient Safety. 2024.
3. U.S. Pharmacopeia. General Chapter <795>: Pharmaceutical Compounding - Nonsterile Preparations. USP 44-NF 39. 2021.
4. U.S. Pharmacopeia. General Chapter <1>: Injections and Implanted Drug Products (Parenterals) - Product Quality Tests. USP 44-NF 39. 2021.
5. International Organization for Standardization. ISO 8537:2016 Sterile single-use syringes, with or without needle, for insulin. 2016.
6. Novo Nordisk. Wegovy (semaglutide) injection prescribing information. 2021.
7. Eli Lilly. Mounjaro (tirzepatide) injection prescribing information. 2022.
8. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
9. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
10. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
11. FDA. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.